ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Operating Margin
- Operating margin · 12 months: Value 7.38%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 7.38% | Operating income / revenue. Period ending 2026-06-30. $34.25M ÷ $463.98M × 100 ≈ 7.38% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 34.25M USD | Operating Income (Loss) |
| Revenue | 463.98M USD | |
| Cost of products and services | 41.10M USD | Cost of Goods and Services Sold |
| Research and development | 91.04M USD | Research and Development Expense |
| Selling, general and administration | 297.60M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34.25M | $463.98M | $41.10M | $91.04M | $297.60M | 7.38% |
| 2026-03-31 | $3.21M | $415.62M | $37.65M | $90.14M | $284.63M | 0.77% |
| 2025-12-31 | $-12.23M | $376.07M | $36.70M | $77.05M | $274.55M | -3.25% |
| 2025-09-30 | $-38.25M | $317.93M | $31.91M | $71.08M | $253.18M | -12.03% |
| 2025-06-30 | $-85.84M | $263.46M | $28.73M | $70.98M | $249.60M | -32.58% |
| 2025-03-31 | $-121.30M | $212.82M | $24.70M | $70.82M | $238.60M | -57.00% |
| 2024-12-31 | $-128.40M | $196.54M | $19.13M | $76.42M | $229.39M | -65.33% |
| 2024-09-30 | $-181.93M | (m) | $14.47M | $85.72M | $220.46M | (m) |
| 2024-06-30 | $-179.77M | (m) | $10.15M | $92.45M | $209.24M | (m) |
| 2024-03-31 | $-196.46M | (m) | $7.46M | $98.37M | $197.02M | (m) |
| 2023-12-31 | $-241.10M | (m) | $4.99M | $110.58M | $185.15M | (m) |
| 2023-09-30 | $-248.36M | (m) | (m) | $120.68M | (m) | (m) |
| 2023-06-30 | $-316.20M | (m) | (m) | $164.17M | (m) | (m) |
| 2023-03-31 | $-315.26M | (m) | (m) | $177.16M | (m) | (m) |
| 2022-12-31 | $-301.63M | (m) | (m) | $182.44M | (m) | (m) |
| 2022-09-30 | $-304.49M | (m) | (m) | $201.12M | (m) | (m) |
| 2022-06-30 | $-256.82M | (m) | (m) | $171.99M | (m) | (m) |
| 2022-03-31 | $-233.07M | (m) | (m) | $164.55M | (m) | (m) |
| 2021-12-31 | $-206.53M | (m) | (m) | $145.56M | (m) | (m) |
| 2021-09-30 | $-169.31M | (m) | (m) | $120.37M | (m) | (m) |
| 2021-06-30 | $-150.53M | (m) | (m) | $112.51M | (m) | (m) |
| 2021-03-31 | $-144.08M | (m) | (m) | $111.76M | (m) | (m) |
| 2020-12-31 | $-136.65M | (m) | (m) | $115.31M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-43.13M | (m) | (m) | $36.52M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-19.73M | (m) | (m) | $17.94M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |